Biora Therapeutics

Executive Summary

Biora Therapeutics is a private biotech company pioneering needle-free oral delivery of large molecule therapeutics, with the goal of replacing injections for chronic disease management. Its two proprietary platforms—BioJet™ for systemic absorption and NaviCap™ for targeted gastrointestinal delivery—address key limitations of traditional biologics administration, including patient adherence and comfort. The company is currently in Phase 1 development, advancing its lead programs through preclinical and early clinical studies. Biora's technology has the potential to unlock new markets for biologics that require frequent injections, such as autoimmune disorders and metabolic diseases. While the company is early-stage and private, its differentiated approach and focus on oral delivery represent a significant opportunity in the biopharma landscape. Upcoming milestones include initial clinical data for the BioJet platform and regulatory progress for NaviCap, which could serve as value inflection points.

Upcoming Catalysts (preview)

• Q3 2026Phase 1 clinical data readout for BioJet platform60% success
• Q2 2026IND submission or clearance for NaviCap platform70% success
• TBDStrategic partnership or licensing deal with a large pharma40% success